

Amendments to the Claims:

The listing of claims below will replace all prior versions and listings of claims in the application. The changes to currently amended claims are shown using strikethrough to identify deleted material and underlining to identify added material.

Listing of Claims:

1. (Currently Amended) A topical ~~anti-inflammatory~~ composition comprising an anti-inflammatory composition consisting essentially of effective amounts of a linseed extract and a licorice extract.
2. (Currently Amended) The topical composition of claim 1 wherein the licorice extract is selected from the group consisting of glycyrrhiza, glycyrrhetic acid, glycyrrhizic acid, derivatives thereof, and combinations thereof.
3. (Currently Amended) The topical composition of claim 2 wherein the derivatives are selected from the group consisting of salts, esters, and a combination thereof.
4. (Currently Amended) The topical composition of claim 3 wherein the salts are selected from the group consisting of metal salts and ammonium salts.
5. (Currently Amended) The topical composition of claim 3 wherein the esters are selected from the group consisting of fatty acid esters, diacid half esters, and glycoside esters.
6. (Currently Amended) The topical composition of claim 5 wherein the fatty acid esters are selected from the group consisting of saturated fatty acid esters and unsaturated fatty acid esters.
7. (Currently Amended) The topical composition of claim 6 wherein the licorice extract is stearyl glycyrrhetinate.

8. (Currently Amended) The topical composition of claim 1 wherein the linseed extract comprises from about 0.00001 to about 10 percent by weight of the topical composition.
9. (Currently Amended) The topical composition of claim 1 wherein the linseed extract comprises from about 0.001 to about 6 percent by weight of the topical composition.
10. (Currently Amended) The topical composition of claim 1 wherein the linseed extract comprises about 4 percent by weight of the topical composition.
11. (Currently Amended) The topical composition of claim 1 wherein the licorice extract comprises from about 0.00001 to about 3 percent by weight of the topical composition.
12. (Currently Amended) The topical composition of claim 8 wherein the stearyl glycyrrhetinate comprises from about 0.0001 to about 2 percent by weight of the topical composition.
13. (Currently Amended) The topical composition of claim 8 7 wherein the stearyl glycyrrhetinate comprises about 0.1 percent by weight of the topical composition.
14. (Currently Amended) The topical composition of claim 1 further comprising at least one bioflavonoid.
15. (Currently Amended) A topical ~~anti-inflammatory~~ composition comprising an anti-inflammatory composition consisting essentially of a linseed extract and a licorice extract, wherein the linseed extract comprises from about 0.1 to about 5 percent by weight of a linseed extract of the topical composition and wherein the licorice extract comprises from about 0.001 to about 1.5 percent by weight of a licorice extract of the topical composition.

16. (Currently Amended) A method of reducing inflammation comprising applying topically to a site of inflammation a topical composition comprising an anti-inflammatory composition consisting essentially of an effective amount amounts of a composition comprising a linseed extract and a licorice extract.

17. (Original) The method of claim 16 wherein the licorice extract is selected from the group consisting of glycyrrhiza, glycyrrhetic acid, glycyrrhizic acid, derivatives thereof, and combinations thereof.

18. (Original) The method of claim 17 wherein the licorice extract is stearyl glycyrrhetinate.

19. (Currently Amended) The method of claim 16 wherein the linseed extract comprises from about 0.00001 to about 10 percent by weight of the topical composition.

20. (Currently Amended) The method of claim 16 wherein the licorice extract comprises from about 0.00001 to about 3 percent by weight of the topical composition.

SUPPORT FOR AMENDMENTS

The amendments to independent claims 1, 15, and 16 are fully supported by the description in the specification (e.g., page 6, paragraph 0023; pages 6-7, paragraph 0025; page 7, paragraph 0026; pages 7-8, paragraph 0028). Dependent claims 2-14 and 19-20 have been clarified in view of the amendments to the base claims. A typographical error in claim 13 was corrected. No new matter has been added. Upon entry of this Response, claims 1-20 remain present and active in the application.